In a study of more than 500 adults, Moderna’s BA.4/BA.5-targeted vaccine proved a “superior” response three months after inoculation, according to the Nov. 14 news release.
Pfizer has not indicated whether it is testing its modified booster for its effectiveness against BQ.1 and BQ.1.1, which currently account for 44.2 percent of U.S. cases, according to CDC data.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
